Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis

NCT05070221 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Stage IV

Interventions

DRUG: Recombinant Oncolytic HSV-2 Therapeutic Injecta (Vero Cell) for Human Use (rHSV2hGM-CSF)
DRUG: Recombinant humanized anti-PD-1 monoclonal antibody for injection
DRUG: Axitinib

Sponsor

Peking University Cancer Hospital & Institute